Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12458917 | 0.85 | KMT2A (0.42) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL14151307 | 0.85 | NOTUM (0.48) | MEN1KMT2AKDM4ENOTUM | |
| SCHEMBL7425205 | 0.84 | SMYD3 (0.50) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL14151866 | 0.84 | PLA2G4A (0.42) | MAPK1SMYD3KDM4EL3MBTL1 | |
| SCHEMBL4891287 | 0.83 | MEN1 (0.44) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL2282033 | 0.81 | CPB2 (0.45) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL2549674 | 0.81 | MEN1 (0.39) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL15775548 | 0.80 | MEN1 (0.43) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL21361934 | 0.80 | MEN1 (0.43) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL21090489 | 0.79 | MEN1 (0.38) | MEN1KMT2AGRM2MAPK1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2537831-B1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2537831-A1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316170-A1 | Imidazole Derivative | S1PR2, S1PR1, SPHK2 | MEN1 1337/4885KMT2A 2089/4885GRM2 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.